Omega Fund Management, LLC holds a concentrated book of 10 stocks worth $163.1M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they trimmed Kestra Medical Technologies. Their largest long position is Bicara Therapeutics Inc at 29% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1637359/holdings"
Use Arkolith to show Omega Fund Management, LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
78% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Bicara Therapeutics Inc. Common Stock | $47.6M | 2.39M | 29.2% | ▲+8.5% Added · +188K sh | |
| 2 | Nuvation Bio Inc. Common Stock Class A | $34.7M | 8.08M | 21.2% | —Held | |
| 3 | BridgeBio Oncology Therapeutics Inc. Common Stock | $29.4M | 3.29M | 18.0% | —Held | |
| 4 | Kestra Med Technologies Ltd Common Stock | $20.4M | 1.02M | 12.5% | ▼−26% Reduced · −351K sh | |
| 5 | Beta Bionics Inc. Common Stock | $13.2M | 1.32M | 8.1% | —Held | |
| 6 | enGene Holdings Inc. Common Stock | $6.0M | 876.4K | 3.7% | —Held | |
| 7 | Alumis Inc. Common Stock | $5.3M | 241.3K | 3.3% | ▼−63% Reduced · −412K sh | |
| 8 | Sana Biotechnology, Inc. Common Stock | $2.4M | 843.8K | 1.5% | —Held | |
| 9 | ImageneBio, Inc. Common Stock | $2.3M | 455.4K | 1.4% | —Held | |
| 10 | Replimune Group Common Stock | $1.9M | 248.7K | 1.2% | —Held |
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.